Webster Stephen W

SEC source: 0000905148-26-003043 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340

Underlying: Common Stock · 2,340 shares

Expires 2036-06-17

F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.

SEC source: 0001193125-26-276057 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,319

Underlying: Common Stock · 25,319 shares

Expires 2026-06-16

F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001193125-26-266279 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,587

Underlying: Common Stock · 13,587 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0000905148-25-002242 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2035-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders.

SEC source: 0000950170-25-086726 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,513

Underlying: Common Stock · 38,513 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

SEC source: 0001415889-25-010435 · form4-04092025_120417.xml · derivative · entry 3

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,379 shares

Expires 2034-06-16

F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.

F3 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.

SEC source: 0001415889-25-010435 · form4-04092025_120417.xml · derivative · entry 2

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,600 shares

Expires 2034-04-25

F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.

F2 · derivative.exercise_date: The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

SEC source: 0001415889-25-010435 · form4-04092025_120417.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value.

SEC source: 0000950170-24-078678 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,806

Underlying: Common Stock · 15,806 shares

Expires 2034-06-26

F1 · derivative.exercise_date: The option represents a right to purchase a total of 15,806 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 26, 2025 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0000905148-24-001769 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders.

SEC source: 0001415889-24-017705 · form4-06202024_090649.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,379

Underlying: Common Stock · 7,379 shares

Expires 2034-06-16

F1 · derivative.exercise_date: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.

SEC source: 0001415889-24-011805 · form4-04302024_100421.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,600

Underlying: Common Stock · 103,600 shares

Expires 2034-04-25

F1 · derivative.exercise_date: The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

SEC source: 0001140361-23-031188 · form4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders.

SEC source: 0000950170-23-027538 · ownership.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,450

Underlying: Common Stock · 18,450 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The option represents a right to purchase a total of 18,450 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 8, 2024 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001104659-23-067057 · tm2317472-7_4seq1.xml · derivative · entry 4

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,482 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067057 · tm2317472-7_4seq1.xml · derivative · entry 3

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,100 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067057 · tm2317472-7_4seq1.xml · derivative · entry 2

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,100 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0001104659-23-067057 · tm2317472-7_4seq1.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,800 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.exercise_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

F2 · derivative.expiration_date: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.

SEC source: 0000899243-22-039006 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2032-12-14

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.

SEC source: 0001104659-22-086279 · tm2222534-11_4seq1.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,447

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001567619-22-013369 · doc1.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders.

SEC source: 0000899243-22-023769 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,475

Underlying: Common Stock · 16,475 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001209191-21-069061 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,100

Underlying: Common Stock · 12,100 shares

Expires 2031-12-08

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.

SEC source: 0000899243-22-012376 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,800

Underlying: Common Stock · 7,800 shares

Expires 2031-09-15

F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001104659-21-100291 · tm2123911-8_4seq1.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,273

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-098424 · tm2123737-4_4seq1.xml · derivative · entry 2

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2031-07-27

F3 · date: The option was granted on July 28, 2021.

F4 · derivative.exercise_date: One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.

SEC source: 0001104659-21-098424 · tm2123737-4_4seq1.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,050

F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units.

F2 · balance_after: The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020.

SEC source: 0001567619-21-012667 · doc1.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2031-06-23

F1 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders.

SEC source: 0000899243-20-033481 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,100

Underlying: Common Stock · 12,100 shares

Expires 2030-12-09

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter.

SEC source: 0001104659-20-089143 · a4.xml · derivative · entry 2

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2030-07-28

F2 · date: The option was granted on July 29, 2020.

F3 · derivative.exercise_date: One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.

SEC source: 0001104659-20-089143 · a4.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,500

F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units.

SEC source: 0001123292-20-000884 · edgar.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.

SEC source: 0001209191-20-026858 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,482

Underlying: Common Stock · 10,482 shares

Expires 2030-04-29

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 30, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

SEC source: 0001209191-20-001425 · doc4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2030-01-02

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 8

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,500 shares

Expires not disclosed

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 7

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 106,015 shares

Expires 2024-07-07

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 6

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2025-03-15

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 5

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2026-01-04

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 4

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2027-01-17

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 3

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,000 shares

Expires 2028-01-17

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · derivative · entry 2

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2029-01-15

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029449 · doc4.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

SEC source: 0001104659-19-043340 · a4.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2029-07-31

F1 · derivative.exercise_price: The exercise price is $2.38 per share.

F2 · derivative.exercise_date: This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc.

SEC source: 0001123292-19-000887 · edgar.xml · derivative · entry 1

Webster Stephen W · CIK 0001438421 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-06-12

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020.

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · derivative · entry 6

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock.

F4 · derivative.exercise_date: On January 18, 2018, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date.

F4 · derivative.expiration_date: On January 18, 2018, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date.

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · derivative · entry 5

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,500

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock.

F3 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date.

F3 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date.

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · nonDerivative · entry 4

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,102

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · nonDerivative · entry 3

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,731

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock.

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · nonDerivative · entry 2

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,731

SEC source: 0001609351-19-000028 · wf-form4_154828182777430.xml · nonDerivative · entry 1

Webster Stephen W · CIK 0001438421 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,365

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock.